Drugs Made In America Acquisition (NASDAQ:DMAA) Trading at $10.88

Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) traded down 0% during mid-day trading on Friday. The stock traded as low as $10.89 and last traded at $10.8850. Approximately 155 shares changed hands during trading, a decline of 99% from the average daily volume of 15,706 shares. The stock had previously closed at $10.89.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Drugs Made In America Acquisition in a report on Wednesday, August 26th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Drugs Made In America Acquisition Price Performance

The business’s fifty day simple moving average is $10.84 and its 200-day simple moving average is $10.63.

Drugs Made In America Acquisition (NASDAQ:DMAA) last issued its quarterly earnings data on Friday, August 14th. The company reported $0.06 EPS for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Drugs Made In America Acquisition stock. Sona Asset Management US LLC acquired a new position in Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 162,795 shares of the company’s stock, valued at approximately $1,706,000. Sona Asset Management US LLC owned 0.48% of Drugs Made In America Acquisition as of its most recent filing with the Securities and Exchange Commission.

Drugs Made In America Acquisition Company Profile

Drugs Made In America Acquisition Corp. (NASDAQ: DMAA) is a special purpose acquisition company (SPAC) formed to identify and complete a business combination with an operating company. Its stated focus is on businesses involved in the development, manufacturing, distribution or commercialization of pharmaceutical products and related healthcare technologies.

The company does not operate as a pharmaceutical manufacturer or healthcare services provider and does not have its own portfolio of drugs, medical products or commercial operations.